Aptose Biosciences Stock Today
| APTO Stock | USD 0.24 0.03 11.11% |
Performance0 of 100
| Odds Of DistressOver 86
|
Aptose Biosciences is selling at 0.24 as of the 22nd of November 2024; that is 11.11 percent decrease since the beginning of the trading day. The stock's open price was 0.27. Aptose Biosciences has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Aptose Biosciences are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 23rd of October 2024 and ending today, the 22nd of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 23rd of October 2014 | Category Healthcare | Classification Health Care |
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada. The company has 19.52 M outstanding shares of which 123.22 K shares are presently shorted by private and institutional investors with about 1.82 trading days to cover. More on Aptose Biosciences
Moving against Aptose Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Aptose Stock Highlights
| Chairman, CEO and Pres | William Rice | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation | |||||
Debt LevelsAptose Biosciences can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Aptose Biosciences' financial leverage. It provides some insight into what part of Aptose Biosciences' total assets is financed by creditors.
| |||||
Aptose Biosciences (APTO) is traded on NASDAQ Exchange in USA. It is located in 251 Consumers Road, Toronto, ON, Canada, M2J 4R3 and employs 35 people. Aptose Biosciences is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 4.76 M. Aptose Biosciences conducts business under Biotechnology sector and is part of Health Care industry. The entity has 19.52 M outstanding shares of which 123.22 K shares are presently shorted by private and institutional investors with about 1.82 trading days to cover.
Aptose Biosciences currently holds about 62.41 M in cash with (44.59 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.68, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Aptose Biosciences Probability Of Bankruptcy
Ownership AllocationAptose Biosciences holds a total of 19.52 Million outstanding shares. Aptose Biosciences shows 15.87 percent of its outstanding shares held by insiders and 16.68 percent owned by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Aptose Ownership Details
Aptose Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Gleason Group, Inc. | 2024-09-30 | 1.2 K | |
| Newbridge Financial Services Group, Inc. | 2024-06-30 | 832 | |
| Advisor Group Holdings, Inc. | 2024-06-30 | 420 | |
| Northwestern Mutual Wealth Management Co | 2024-06-30 | 133 | |
| Group One Trading, Lp | 2024-06-30 | 115 | |
| Federation Des Caisses Desjardins Du Quebec | 2024-06-30 | 102 | |
| Pacific Capital Wealth Advisors, Inc | 2024-09-30 | 6.0 | |
| Citigroup Inc | 2024-06-30 | 1.0 | |
| Fidelity International Ltd | 2024-06-30 | 1.0 | |
| Armistice Capital, Llc | 2024-06-30 | 1.7 M | |
| Drw Securities, Llc | 2024-06-30 | 592.8 K |
Aptose Biosciences Historical Income Statement
Aptose Stock Against Markets
Aptose Biosciences Corporate Management
| Brooks MBA | VP Controller | Profile | |
| Philippe Ledru | Senior Officer | Profile | |
| Janet CA | VP Fin | Profile | |
| Rafael MD | Senior Officer | Profile | |
| Roger BSc | Vice Operations | Profile | |
| Marc Wiles | Senior Affairs | Profile |
Already Invested in Aptose Biosciences?
The danger of trading Aptose Biosciences is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Aptose Biosciences is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Aptose Biosciences. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Aptose Biosciences is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Aptose Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Aptose Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Aptose Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Aptose Biosciences Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aptose Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. To learn how to invest in Aptose Stock, please use our How to Invest in Aptose Biosciences guide.You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aptose Biosciences. If investors know Aptose will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aptose Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.92) | Return On Assets (1.36) | Return On Equity (6.94) |
The market value of Aptose Biosciences is measured differently than its book value, which is the value of Aptose that is recorded on the company's balance sheet. Investors also form their own opinion of Aptose Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Aptose Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aptose Biosciences' market value can be influenced by many factors that don't directly affect Aptose Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aptose Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aptose Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aptose Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.